Intellia Broadens Its Oncology Bets With CRISPR-Edited NK Cell Therapies
Partners ONK Therapeutics To Develop Five Candidates
Intellia is using its CRISPR technology for in vivo and ex vivo applications, the latter focused on next-gen cancer immunotherapies. • Source: Alamy 
